SHANGHAI, Feb. 28, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines, today announced that it will hold investor calls to discuss recent developments on its mRNA therapeutic vaccine programs.
The English session of the conference call will be held at 9:00 pm on March 6, 2025 Beijing Time (8:00 am U.S. Eastern Time on March 6), and the Mandarin session of the conference call will be held at 9:00 am Beijing Time on March 7, 2025 (8:00 pm U.S. Eastern Time on March 6).
The conference calls can be accessed by the following links:
For English Session:
Time: 9:00 pm Beijing Time, Thursday, March 6, 2025 (8:00 am U.S. Eastern Time, March 6)
Pre-Registration Link:
Webcast Link:
Alternatively, participants may dial in to the conference call using below dial-in information:
United States:
+1-646-2543594 (EN)
Chinese Mainland:
+86-10-58084166 (EN)
+86-10-58084199 (CN)
Hong Kong, China:
+852-30051313 (EN)
+852-30051355 (CN)
United Kingdom:
+44(12)1368-0466 (EN)
International:
+1-866-6363243 (EN)
Password:
798635
For Mandarin Session:
Time: 9:00 am Beijing Time, Friday, March 7, 2025 (8:00 pm U.S. Eastern Time on March 6).
Webcast Link: https://s.comein.cn/9y4tyiy1
Alternatively, participants may dial into the conference call using below dial-in information:
United States:
+1-646-3578788
+1-408-7093255
Chinese Mainland:
400-969-8928
400-806-3263
Hong Kong, China:
+852-301-83602
Taiwan, China:
+886-226563394
+886-277417882
Singapore:
+65-64075649
+65-66220840
United Kingdom:
+44-2070970018
International:
+86-2362737123
Password:
185008
The replay of English session will be available shortly after the call and can be accessed by visiting the Company's website at .
About Everest Medicines
Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines that address critical unmet medical needs for patients in Asian markets. The management team of Everest Medicines has deep expertise and an extensive track record from both leading global pharmaceutical companies and local Chinese pharmaceutical companies in high-quality discovery, clinical development, regulatory affairs, CMC, business development and operations. Everest Medicines has built a portfolio of potentially global first-in-class or best-in-class molecules in the company's core therapeutic areas of renal diseases, infectious diseases and autoimmune disorders. For more information, please visit its website at .
Forward-Looking Statements:
This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.